Summary of the Conference Call for Ruizhi Pharmaceutical Company Overview - **Company**: Ruizhi Pharmaceutical - **Industry**: Pharmaceutical and Biotechnology Key Points and Arguments Financial Performance - In Q1 2025, Ruizhi Pharmaceutical reported revenue of **261 million yuan**, a year-on-year increase of **11.37%** [2][4] - The net profit attributable to shareholders was **6.64 million yuan**, marking a return to profitability [2][4] - The company significantly reduced its non-deductible net profit loss to **1.57 million yuan**, a **94%** reduction in losses year-on-year [2][5] - For 2024, the company faced challenges with revenue dropping to **970 million yuan**, a **14.76%** decline, and a net loss of **226 million yuan**, although this was a **75.49%** improvement compared to the previous year [3] Strategic Initiatives - The company is implementing a comprehensive package strategy, providing one-stop solutions from IND to PCC, enhancing service capabilities across the entire chain [2][6] - Focus on high-value orders and investment in new modalities such as ADC, RDC, AOC, and PDC [2][6] - Initiated a partnership with leading companies in the ADC field to launch a new generation XDC conjugate drug R&D technology platform [2][7] Market Development - Emphasis on large clients in the domestic market, targeting traditional markets transitioning to innovation [2][8] - Optimizing the business development (BD) team for deeper engagement in the U.S. market and increasing exposure in emerging European markets [2][8] - Plans to establish new R&D centers on the U.S. East Coast and in the UK [2][8] Equity Incentive Plan - The company approved an equity incentive plan granting **52.61 million shares**, representing **10.57%** of total equity, to **124 core personnel** [2][9] - Performance targets include a **25%** increase in revenue and a return to profitability [2][9] Business Segment Insights - The small molecule drug segment is experiencing sluggish growth, needing significant effort to return to previous peak levels of **400-500 million yuan** [3][11] - The company is seeing rapid growth in high-risk related businesses, with domestic growth particularly boosted by recent large projects [3][11] ADC Business Capabilities - The company has comprehensive capabilities in the ADC sector, including chemistry, conjugation, and antibody development [2][12] - Currently rebuilding ABC CNC production capacity, with plans to initiate operations soon [2][12] Organizational Changes - The BD structure has been reformed to enhance domestic market engagement, which previously accounted for over **80%** of revenue from international orders [2][13] - New strategies include regional divisions and a focus on strategic client resources [2][13] Future Outlook - The management expresses confidence in achieving annual targets, supported by external market recovery and internal optimization [2][10] - The company is optimistic about future growth, especially in the innovative drug sector, as traditional pharmaceutical companies increase their investments [2][16][22] Investment Fund Strategy - Since 2022, the company has participated in investment funds to drive business development, leveraging government-guided funds for early-stage incubation [2][19] Market Recovery - The overseas market is showing signs of recovery, with a notable return of funds to primary markets [2][17] Emerging Market Trends - ADC, peptides, and small nucleotides are identified as high-growth areas, with the company securing multiple projects in these fields [2][18] Additional Important Insights - The company is focused on cost control while investing in platform development, including small nucleic acid drug platforms and ABC development [2][14] - The second quarter shows positive trends, with traditional pharmaceutical companies increasing their investment in innovative drugs [2][15]